Utilization of recombinant activated factor VII for intracranial hematoma evacuation in coagulopathic nonhemophilic neurosurgical patients with normal international normalized ratios

By McClelland Shearwood   Won Eun   Lam Cornelius  

Neurocritical Care, Vol. 7, Iss. 2, 2007-10 ,pp. : 136-139

Humana Press, Inc

Access to resources Recommend Favorite

Ten‐year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan

By  

HAEMOPHILIA, Vol. 21, Iss. 3, 2015-05 ,pp. : 374-379

John Wiley & Sons Inc

Access to resources Recommend Favorite

Use of Recombinant Factor VIIa in Patients With Warfarin-Associated Intracranial Hemorrhage

By Brody David L.   Aiyagari Venkatesh   Shackleford Angela M.   Diringer Michael N.  

Neurocritical Care, Vol. 2, Iss. 3, 2005-06 ,pp. : 263-267

Humana Press, Inc

Access to resources Recommend Favorite

Systemic Hemostasis With Recombinant-Activated Factor VII Followed by Local Thrombolysis With Recombinant Tissue Plasminogen Activator in Intraventricular Hemorrhage

By Ionita Catalina C.   Ferrara Joseph   McDonagh David L.   Grossi Peter   Graffagnino Carmelo  

Neurocritical Care, Vol. 3, Iss. 3, 2005-12 ,pp. : 246-248

Humana Press, Inc

Access to resources Recommend Favorite

Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on‐demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain

By  

HAEMOPHILIA, Vol. 21, Iss. 3, 2015-05 ,pp. : 320-329

John Wiley & Sons Inc

Access to resources Recommend Favorite